Search research articles
Contact Us
Filters
Showing results (581-590 of 1,058) with videos related to
Page
of 106
Sort By:
British Journal of Haematology
|
December 18, 2009
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease
Jennifer A Woyach, Nyla A Heerema, John Zhao, et al.
Journal of the American Chemical Society
|
July 24, 2023
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from Cubanes
Jeong-Yu Son, Santeri Aikonen, Nathan Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Leukemia & Lymphoma
|
February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
John C Byrd, Susan O'Brien, Ian W Flinn, et al.
British Journal of Haematology
|
April 8, 2011
OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway
Li-Yuan Bai, Yihui Ma, Samuel K Kulp, et al.
Leukemia & Lymphoma
|
November 19, 2020
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia
Soun Khountham, Polina Shindiapina, Xiaokui Mo, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 26, 2020
Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML
Nathaniel J Buteyn, Ramasamy Santhanam, Giovanna Merchand-Reyes, et al.
Leukemia
|
July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A J Johnson, Y-Y Yeh, L L Smith, et al.
International Journal of Pharmaceutics
|
September 10, 2008
A novel liposomal formulation of flavopiridol
Xiaojuan Yang, Xiaobin Zhao, Mitch A Phelps, et al.
Page
of 106
Search research articles
Search
Showing results (581-590 of 1,058) with videos related to
Sort By:
Page
of 106
British Journal of Haematology
|
December 18, 2009
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease
Jennifer A Woyach, Nyla A Heerema, John Zhao, et al.
Journal of the American Chemical Society
|
July 24, 2023
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from Cubanes
Jeong-Yu Son, Santeri Aikonen, Nathan Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Leukemia & Lymphoma
|
February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
John C Byrd, Susan O'Brien, Ian W Flinn, et al.
British Journal of Haematology
|
April 8, 2011
OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway
Li-Yuan Bai, Yihui Ma, Samuel K Kulp, et al.
Leukemia & Lymphoma
|
November 19, 2020
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia
Soun Khountham, Polina Shindiapina, Xiaokui Mo, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 26, 2020
Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML
Nathaniel J Buteyn, Ramasamy Santhanam, Giovanna Merchand-Reyes, et al.
Leukemia
|
July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A J Johnson, Y-Y Yeh, L L Smith, et al.
International Journal of Pharmaceutics
|
September 10, 2008
A novel liposomal formulation of flavopiridol
Xiaojuan Yang, Xiaobin Zhao, Mitch A Phelps, et al.
Page
of 106